|Initial Investment:||September 2015|
|Lead Partner:||John Cambier|
Lucerno provides oncologists a quantitative assessment of tumor response to treatment; thus, identifying effective therapy, improving patient outcomes and dramatically reducing costs. Lucerno also has potential to aid oncologists in initial treatment selection and speed oncology drug development.
MORRISVILLE, N.C. — Lucerno Dynamics, a Morrisville company developing noninvasive sensor technology that can show the effectiveness of radiotracer injections in patients undergoing PET/CT scans, has launched a nationwide study to demonstrate the benefits of its system. The study, called “Lara-Q1,” is to enroll more than 10,000 patients in up to a dozen sites around […]
Lucerno Dynamics – which recently completed its series A equity funding round, raising $6.34 million – has a commercially available device and has launched a new study with it. The Morrisville-based company’s Class 1 device, the Lara System, is now listed with the U.S. Food and Drug Administration. The device detects and monitors infiltrations of […]
Morrisville, NC – October 10, 2016 – Lucerno Dynamics, LLC, a medical device start-up in Morrisville, NC, announces the completion of its series A equity funding round with a total $6.34 million raised. “We are very pleased with the response to our fundraising campaign,” said Ron Lattanze, Lucerno’s chief executive officer. “This completes our funding […]
1415 W NC Hwy 54, Suite 206
Durham, NC 27707